Executive Decisions Roundup
This article was originally published in The Tan Sheet
Hamburg joins IoM as foreign secretary; more people news in brief.
You may also be interested in...
Yin Li becomes director of China’s State FDA, taking the reins from Shao Mingli, who led the agency since 2005. Yin’s work as vice minister of health touched on a broad swath of pharmaceutical manufacturing regulation and food safety enforcement.
Biodegradable plastic alternatives for use in cosmetic products were left unaddressed, and thus arguably unusable, under the US Microbead-Free Waters Act enacted in late 2015. European industry stakeholders now face the prospect of a far more extensive microplastic ban, and the viability of bioplastics to replace conventional, petroleum-based microplastics is an area in need of work.
Most of the foreign OTC drug firms targeted in latest warnings FDA published, including the GUM oral care brand manufacturer, were placed on import alert due to GMP violations. Each was inspected by FDA during June, July or May 2019, when the agency was wrapping up an initiative to inspect all previously uninspected drug manufacturers.